Table 3: Predictors of achieving an SVR among all patients.
| Variable | Univariate analysis OR (95% CI) |
Multivariate analysis adjusted OR (95% CI) |
|---|---|---|
| Age | 0.95 (0.90-0.99) | 0.95 (0.90-1.00) |
| Male sex | 0.28 (0.10-0.84) | 0.30 (0.10-0.89) |
| Previous treatment | 0.82 (0.34-1.97) | - |
| Genotype 1a | 1.34 (0.59-3.03) | - |
| FibroScan measurement at baseline (per kPa) | 0.99 (0.97-1.02) | - |
| Viremia (per 1000 IU) | 1.00 (0.99-1.02) | - |
| Cirrhosis at baseline | 0.39 (0.17-0.91) | 0.56 (0.23-1.36) |
| Treated according to guidelines | 1.09 (0.36-3.32) | - |
| Previous history of hepatocellular carcinoma | 0.27 (0.08-0.88) | 0.37 (0.11-1.28) |
| MELD score at baseline | 1.76 (0.35-8.97) | - |
| MELD with sodium score at baseline | 1.01 (0.78-1.31) | - |
Note: CI = confidence interval, MELD = model for end-stage liver disease, OR = odds ratio, SVR = sustained viral response.